{"id":"glanatec","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"trials":[],"_chembl":null,"aliases":["Ripasudil"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"mechanism":{"target":"Serine/threonine-protein kinase TAO3, 5'-AMP-activated protein kinase subunit gamma-1, Aurora kinase B"},"_scrapedAt":"2026-03-28T02:38:32.979Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Glaucoma","diseaseId":"glaucoma","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Ocular hypertension","diseaseId":"ocular-hypertension","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05795699","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-03-30","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":107},{"nctId":"NCT05826353","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2023-05-11","conditions":"Fuchs Endothelial Corneal Dystrophy","enrollment":110},{"nctId":"NCT05275972","phase":"PHASE3","title":"Descemet Endothelial Thickness Comparison Trial II","status":"RECRUITING","sponsor":"Stanford University","startDate":"2023-01-23","conditions":"Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy","enrollment":60},{"nctId":"NCT05289661","phase":"PHASE3","title":"Descemet Endothelial Thickness Comparison Trial I","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stanford University","startDate":"2022-07-15","conditions":"Fuchs","enrollment":160},{"nctId":"NCT05636579","phase":"PHASE1","title":"Study to Assess Safety and Tolerability of Multiple Doses of EO2002","status":"RECRUITING","sponsor":"Asociación para Evitar la Ceguera en México","startDate":"2022-11-08","conditions":"Corneal Edema, Corneal Endothelial Dystrophy, Endothelial Dysfunction","enrollment":12},{"nctId":"NCT06048380","phase":"PHASE3","title":"The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery","status":"RECRUITING","sponsor":"Singapore Eye Research Institute","startDate":"2025-03-01","conditions":"Fuchs' Endothelial Dystrophy, Cataract","enrollment":120},{"nctId":"NCT05528172","phase":"PHASE3","title":"A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery","status":"COMPLETED","sponsor":"Kowa Research Institute, Inc.","startDate":"2022-08-04","conditions":"Corneal Edema After Cataract Surgery","enrollment":331},{"nctId":"NCT03813056","phase":"PHASE2","title":"Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy","status":"RECRUITING","sponsor":"Michael D. Straiko, MD","startDate":"2019-03-25","conditions":"Fuchs Endothelial Dystrophy","enrollment":72},{"nctId":"NCT04620135","phase":"PHASE3","title":"Efficacy and Safety Study of Netarsudil 0.02% Ophthalmic Solution Compared to Ripasudil Hydrochloride Hydrate 0.4% Ophthalmic Solution in Japanese Subjects With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Aerie Pharmaceuticals","startDate":"2020-11-30","conditions":"Primary Open Angle Glaucoma, Ocular Hypertension","enrollment":245},{"nctId":"NCT04621136","phase":"PHASE1, PHASE2","title":"PhaseI/II Investigator-Initiated Trial to Investigate Safety and Efficacy of Ripasudil in Patients With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Kyushu University","startDate":"2020-11-01","conditions":"Retinopathy of Prematurity","enrollment":24},{"nctId":"NCT03249337","phase":"PHASE4","title":"Glanatec(R) for Descemet Stripping in Fuch's Endothelial Dystrophy","status":"RECRUITING","sponsor":"Marian Macsai, MD","startDate":"2017-12-06","conditions":"Fuchs' Endothelial Dystrophy","enrollment":30},{"nctId":"NCT03575130","phase":"PHASE2","title":"Ripasudil 0.4% Eye Drops in Fuchs Endothelial Corneal Dystrophy","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2018-06-05","conditions":"Fuchs' Endothelial Dystrophy, Fuchs Dystrophy, Corneal Endothelial Dystrophy","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":11,"therapeuticAreas":["Cardiovascular"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"phase_2","status":"active","brandName":"Glanatec","genericName":"Glanatec","companyName":"Michael D. Straiko, MD","companyId":"michael-d-straiko-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":5,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}